For the manufacture of its proprietary dengue vaccine for human clinical trials, InViragen has entered into an agreement with Shantha Biotechnics (Hyderabad, India) - the first Indian company to develop, manufacture and market a recombinant human healthcare product in India.
The materials that will be made under this agreement will be used by InViragen to complete preclinical studies and initiate testing of the vaccine for safety and efficacy in human volunteers.
InViragen's dengue vaccine was designed by collaborators at the Centers for Disease Control and Prevention (CDC) to protect against all four of the dengue viruses. The vaccine has been shown to be safe and effective in preclinical animal models.Read the full press release.
Comment Preview